Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C

B. J. Veldt, J. J. Poterucha, K. D S Watt, R. H. Wiesner, J. E. Hay, C. B. Rosen, J. K. Heimbach, H. L A Janssen, M. R. Charlton

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

In the nontransplant setting diabetes mellitus is a risk factor for disease progression in patients with chronic hepatitis C virus (HCV) infection. The impact of early insulin resistance on the development of advanced fibrosis, even in the absence of clinically apparent diabetes mellitus, is not known. Our aim was to determine whether the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) can be used to identify insulin-resistant patients at risk for rapid fibrosis progression. Cohort study including patients transplanted for chronic HCV between January 1, 1995 and January 1, 2005. One hundred sixty patients were included; 25 patients (16%) were treated for diabetes mellitus and 36 patients (23%) were prediabetic, defined as HOMA-IR >2.5. Multivariate Cox regression analysis showed that insulin resistance (hazard ratio (HR) 2.07; confidence interval (CI) 1.10-3.91, p = 0.024), donor age (HR 1.33;CI 1.08-1.63, p = 0.007) and aspartate aminotransferase (HR 1.03;CI 1.01-1.05, p < 0.001) were significantly associated with a higher probability of developing advanced fibrosis, i.e. Knodell fibrosis stage 3 or 4, whereas steatosis (HR 0.94;CI 0.46-1.92, p = 0.87) and acute cellular rejection (HR 1.72;CI 0.88-3.36, p = 0.111) were not. In conclusion, posttransplant insulin resistance is strongly associated with more severe recurrence of HCV infection. HOMA-IR is an important tool for the identification of insulin resistance among patients at risk for rapid fibrosis progression after liver transplantation for HCV.

Original languageEnglish (US)
Pages (from-to)1406-1413
Number of pages8
JournalAmerican Journal of Transplantation
Volume9
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Adipokines
Hepatitis C
Insulin Resistance
Fibrosis
Hepacivirus
Confidence Intervals
Serum
Diabetes Mellitus
Homeostasis
Chronic Hepatitis C
Virus Diseases
Aspartate Aminotransferases
Liver Transplantation
Disease Progression
Cohort Studies
Regression Analysis
Tissue Donors
Insulin
Recurrence

Keywords

  • Hepatitis C virus
  • Liver transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Veldt, B. J., Poterucha, J. J., Watt, K. D. S., Wiesner, R. H., Hay, J. E., Rosen, C. B., ... Charlton, M. R. (2009). Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. American Journal of Transplantation, 9(6), 1406-1413. https://doi.org/10.1111/j.1600-6143.2009.02642.x

Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. / Veldt, B. J.; Poterucha, J. J.; Watt, K. D S; Wiesner, R. H.; Hay, J. E.; Rosen, C. B.; Heimbach, J. K.; Janssen, H. L A; Charlton, M. R.

In: American Journal of Transplantation, Vol. 9, No. 6, 06.2009, p. 1406-1413.

Research output: Contribution to journalArticle

Veldt, BJ, Poterucha, JJ, Watt, KDS, Wiesner, RH, Hay, JE, Rosen, CB, Heimbach, JK, Janssen, HLA & Charlton, MR 2009, 'Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C', American Journal of Transplantation, vol. 9, no. 6, pp. 1406-1413. https://doi.org/10.1111/j.1600-6143.2009.02642.x
Veldt, B. J. ; Poterucha, J. J. ; Watt, K. D S ; Wiesner, R. H. ; Hay, J. E. ; Rosen, C. B. ; Heimbach, J. K. ; Janssen, H. L A ; Charlton, M. R. / Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. In: American Journal of Transplantation. 2009 ; Vol. 9, No. 6. pp. 1406-1413.
@article{a21c47657f7a4e9085ce4157f6671d49,
title = "Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C",
abstract = "In the nontransplant setting diabetes mellitus is a risk factor for disease progression in patients with chronic hepatitis C virus (HCV) infection. The impact of early insulin resistance on the development of advanced fibrosis, even in the absence of clinically apparent diabetes mellitus, is not known. Our aim was to determine whether the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) can be used to identify insulin-resistant patients at risk for rapid fibrosis progression. Cohort study including patients transplanted for chronic HCV between January 1, 1995 and January 1, 2005. One hundred sixty patients were included; 25 patients (16{\%}) were treated for diabetes mellitus and 36 patients (23{\%}) were prediabetic, defined as HOMA-IR >2.5. Multivariate Cox regression analysis showed that insulin resistance (hazard ratio (HR) 2.07; confidence interval (CI) 1.10-3.91, p = 0.024), donor age (HR 1.33;CI 1.08-1.63, p = 0.007) and aspartate aminotransferase (HR 1.03;CI 1.01-1.05, p < 0.001) were significantly associated with a higher probability of developing advanced fibrosis, i.e. Knodell fibrosis stage 3 or 4, whereas steatosis (HR 0.94;CI 0.46-1.92, p = 0.87) and acute cellular rejection (HR 1.72;CI 0.88-3.36, p = 0.111) were not. In conclusion, posttransplant insulin resistance is strongly associated with more severe recurrence of HCV infection. HOMA-IR is an important tool for the identification of insulin resistance among patients at risk for rapid fibrosis progression after liver transplantation for HCV.",
keywords = "Hepatitis C virus, Liver transplantation",
author = "Veldt, {B. J.} and Poterucha, {J. J.} and Watt, {K. D S} and Wiesner, {R. H.} and Hay, {J. E.} and Rosen, {C. B.} and Heimbach, {J. K.} and Janssen, {H. L A} and Charlton, {M. R.}",
year = "2009",
month = "6",
doi = "10.1111/j.1600-6143.2009.02642.x",
language = "English (US)",
volume = "9",
pages = "1406--1413",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C

AU - Veldt, B. J.

AU - Poterucha, J. J.

AU - Watt, K. D S

AU - Wiesner, R. H.

AU - Hay, J. E.

AU - Rosen, C. B.

AU - Heimbach, J. K.

AU - Janssen, H. L A

AU - Charlton, M. R.

PY - 2009/6

Y1 - 2009/6

N2 - In the nontransplant setting diabetes mellitus is a risk factor for disease progression in patients with chronic hepatitis C virus (HCV) infection. The impact of early insulin resistance on the development of advanced fibrosis, even in the absence of clinically apparent diabetes mellitus, is not known. Our aim was to determine whether the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) can be used to identify insulin-resistant patients at risk for rapid fibrosis progression. Cohort study including patients transplanted for chronic HCV between January 1, 1995 and January 1, 2005. One hundred sixty patients were included; 25 patients (16%) were treated for diabetes mellitus and 36 patients (23%) were prediabetic, defined as HOMA-IR >2.5. Multivariate Cox regression analysis showed that insulin resistance (hazard ratio (HR) 2.07; confidence interval (CI) 1.10-3.91, p = 0.024), donor age (HR 1.33;CI 1.08-1.63, p = 0.007) and aspartate aminotransferase (HR 1.03;CI 1.01-1.05, p < 0.001) were significantly associated with a higher probability of developing advanced fibrosis, i.e. Knodell fibrosis stage 3 or 4, whereas steatosis (HR 0.94;CI 0.46-1.92, p = 0.87) and acute cellular rejection (HR 1.72;CI 0.88-3.36, p = 0.111) were not. In conclusion, posttransplant insulin resistance is strongly associated with more severe recurrence of HCV infection. HOMA-IR is an important tool for the identification of insulin resistance among patients at risk for rapid fibrosis progression after liver transplantation for HCV.

AB - In the nontransplant setting diabetes mellitus is a risk factor for disease progression in patients with chronic hepatitis C virus (HCV) infection. The impact of early insulin resistance on the development of advanced fibrosis, even in the absence of clinically apparent diabetes mellitus, is not known. Our aim was to determine whether the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) can be used to identify insulin-resistant patients at risk for rapid fibrosis progression. Cohort study including patients transplanted for chronic HCV between January 1, 1995 and January 1, 2005. One hundred sixty patients were included; 25 patients (16%) were treated for diabetes mellitus and 36 patients (23%) were prediabetic, defined as HOMA-IR >2.5. Multivariate Cox regression analysis showed that insulin resistance (hazard ratio (HR) 2.07; confidence interval (CI) 1.10-3.91, p = 0.024), donor age (HR 1.33;CI 1.08-1.63, p = 0.007) and aspartate aminotransferase (HR 1.03;CI 1.01-1.05, p < 0.001) were significantly associated with a higher probability of developing advanced fibrosis, i.e. Knodell fibrosis stage 3 or 4, whereas steatosis (HR 0.94;CI 0.46-1.92, p = 0.87) and acute cellular rejection (HR 1.72;CI 0.88-3.36, p = 0.111) were not. In conclusion, posttransplant insulin resistance is strongly associated with more severe recurrence of HCV infection. HOMA-IR is an important tool for the identification of insulin resistance among patients at risk for rapid fibrosis progression after liver transplantation for HCV.

KW - Hepatitis C virus

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=66249095118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66249095118&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2009.02642.x

DO - 10.1111/j.1600-6143.2009.02642.x

M3 - Article

C2 - 19459812

AN - SCOPUS:66249095118

VL - 9

SP - 1406

EP - 1413

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 6

ER -